Form 8-K - Current report:
SEC Accession No. 0001437749-20-002938
Filing Date
2020-02-18
Accepted
2020-02-18 17:30:00
Documents
2
Period of Report
2020-02-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20200218_8k.htm 8-K 28206
2 EXHIBIT 5.1 ex_173084.htm EX-5.1 7643
  Complete submission text file 0001437749-20-002938.txt   37149
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 20626557
SIC: 2835 In Vitro & In Vivo Diagnostic Substances